This is the same manuscript that was previously made available as a pre-peer review bioRxiv paper. It is now peer reviewed and published in Nature. The Nature version includes an additional section "Antiviral activity of host-directed drugs and compounds" that was not in the bioRxiv version. Long story, short....RVX-208 did not have anti-viral activity in the Mt Sinai NYC test or the Institut Pasteur in Paris test. From the new section in Nature:

"We next investigated the antiviral activity of these drugs and compounds, employing two viral assays (Fig. 6a). First, at Mt Sinai Hospital in New York, we developed a medium-throughput immunofluorescence-based assay (detecting the viral NP protein) to screen 37 compounds for inhibition of SARS-CoV-2 infection in the Vero E6 cell line. Second, at the Institut Pasteur in Paris, viral RNA was monitored using qRT-PCR upon treatment with 44 drugs and compounds. Together, both locations tested 47 of the 69 compounds we identified, plus 13 to expand testing at the SigmaR1/R2 receptors and mRNA translation targets, and 15 additional molecules prioritized by other methods (see Methods and Supplementary Table 6). Viral growth and cytotoxicity were monitored at both institutions (Extended Data Figs. 8 & 9; Supplementary Table 6)."